# Study of ESG401 in Adults With Solid Tumors

Source: https://onco.cc/trials/nct04892342/  
OnCo record `nct04892342` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

An early trial studying the safety and activity of experimental treatment. Its registry status does not establish patient benefit.

## Summary

Study of ESG401 in Adults With Solid Tumors. ClinicalTrials.gov record last updated 2025-09-12: completed. Enrollment is actual at 156 participants. Primary completion is actual at 2025-06-30. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-10-06
- Registry id: NCT04892342
- Phase: 1/2
- Setting: Study of ESG401 in Adults With Solid Tumors
- Sponsor: Shanghai Escugen Biotechnology Co., Ltd
- Enrolled: 156

## Notes

- ClinicalTrials.gov record last updated 2025-09-12: completed. Enrollment is actual at 156 participants. Primary completion is actual at 2025-06-30. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications.

## Sources

- ClinicalTrials.gov NCT04892342: https://clinicaltrials.gov/study/NCT04892342

## Connected records

- targets: [TROP2](https://onco.cc/targets/trop2/)
- drugs: [ESG401](https://onco.cc/drugs/esg401/)

---
JSON: https://onco.cc/api/v1/entities/nct04892342.json